Home > Pipelines > Overview


NBHL conducts proprietary drug discovery programs focused on respiratory diseases, chronic inflammation and central nervous system (CNS) disorders. We are open to discussing these internal programs with pharmaceutical partners on an ongoing basis and are seeking partners for clinical development and commercialization.

Internal pipelines are available for partnering opportunity
Project Indication Drug type Target molecule Patent Status
P001 Cancer immunity
Autoimmune disease
mAb EP4 Issued Optimization of mAb
P007 Lung fibrosis
Kidney fibrosis
mAb Chemokine GPCR Issued Prior to GLP test & CMC
P005 Sleeping disorder
Alzheimer’s disease
small molecule CK1σ Issued Optimization toward preclinical
P013 Lung fibrosis
mAb Lipid mediator GPCR Discovery